Emmaus Life Sciences
OTCMKTS:EMMAEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
Inhibikase Therapeutics
NYSE:IKTInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
OmniComm Systems
OTCMKTS:OMCMOmniComm Systems, Inc., a healthcare technology company, provides Web-based electronic data capture (EDC), and eClinical software and services for pharmaceutical and biotechnology companies, clinical research organizations (CROs), and other clinical trial sponsors worldwide. It offers TrialMaster, which allows organizations conducting clinical trials to collect and manage the data over the Internet; TrialOne Phase I Clinic Automation, a software application suite that provides clinical trial site sponsors, study investigators, and study monitors with various tools to conduct the Phase I clinic operation; and IRTMaster, which offers interactive response technology in support of the randomization process in clinical trials. The company also provides eClinical Suite that comprises a set of tools for collecting and managing clinical data, including EDC for real-time entry and double data entry (DDE) for entry from paper originals; and Promasys, a clinical trial data management system for DDE and EDC, which is primarily used at research institutions for investigator-initiated trials. In addition, it offers Acuity, a clinical data aggregation and analytics platform that provides actionable insights into quality, risk, and performance of various aspects of clinical trials in real time. Further, the company provides consulting and professional services, such as project management, clinical services, training, custom configuration, system integration, standard operating procedures and implementation assistance, installation, and validation services, as well as application hosting and related support services. It sells its products through a direct sales force and relationships with CRO partners, as well as through co-marketing agreements with vendor and channel partners. OmniComm Systems, Inc. was founded in 1996 and is headquartered in Fort Lauderdale, Florida.
RegeneRx Biopharmaceuticals
OTCMKTS:RGRXRegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
ReWalk Robotics
NASDAQ:RWLKReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.